Elopram 5 mg (Tablet)

Unit Price: ৳ 7.00 (5 x 10: ৳ 350.00)

Strip Price: ৳ 70.00

Medicine Details

Orally administered selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic and benzodiazepine receptors

Usual dosage is 10 mg once daily for major depressive episodes
An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily for panic disorder
Initial dosage is 10 mg once daily for social anxiety disorder
Initial dosage is 10 mg once daily for generalized anxiety disorder
Initial dosage is 10 mg once daily for obsessive-compulsive disorder

SSRI or related antidepressants should not be started until 2 weeks after stopping a monoamine oxidase inhibitor (MAOI)
An MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case of paroxetine and sertraline, at least 5 weeks in the case of fluoxetine)

Contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients of the drug product
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

Less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Gastrointestinal effects include nausea, vomiting, dyspepsia, abdominal pain, diarrhea, constipation
Anorexia with weight loss, increased appetite and weight gain also reported
Hypersensitivity reactions including rash, urticaria, angioedema, anaphylaxis
Other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

Carefully consider potential risks and benefits of treatment when treating a pregnant woman with Escitalopram during the third trimester
Excreted in human breast milk, decision whether to continue or discontinue nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits of Escitalopram treatment for the mother

Use with caution in patients with epilepsy, cardiac disease, diabetes mellitus, angle-closure glaucoma, hepatic and renal impairment
Avoid if poorly controlled epilepsy, discontinue if convulsions develop
Prolonged seizures reported with fluoxetine in concurrent electroconvulsive therapy
Use with caution in patients with history of mania, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders, and hepatic and renal impairment

Initial dosage is 5 mg once daily for elderly patients (>65 years of age)
Elopram should not be used in the treatment of children and adolescents under the age of 18 years
Dosage adjustment is not necessary in patients with mild or moderate renal impairment
An initial dose of 5 mg daily for the first two weeks in patients with mild or moderate hepatic impairment
For poor metabolizers of CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended

Symptoms include dizziness, tremor, agitation, serotonin syndrome, convulsion, coma, nausea, vomiting, hypotension, tachycardia, QT interval prolongation, arrhythmia, hypokalemia, hyponatremia
No specific antidote, general symptomatic supportive measures recommended